HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results

Nearing Completion of Patient Recruitment in
FDA Pivotal Clinical Validation Study of MyoVista®

Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year